CGS-authored

When life-science executives gathered for the California Health Care Institute's annual public forum just days after the November election, the event felt at times like a victory lap for backers of California's $3 billion stem-cell measure.

But if some back-patting was going on, the event was not without its more sobering moments.

State Sen. Deborah Ortiz, D-Sacramento, who authored legislation that gave rise to the measure, warned the audience at Stanford University that as the newly established California Institute for Regenerative Medicine races into being, it must set up guidelines that provide transparency, protect against conflicts of interest and ensure that Californians will enjoy the financial and health benefits that their investment yields. All the while, the health of women who donate their eggs for stem-cell research must be protected, she said.

It was the opening salvo in what threatens to become a legislative battle over the guidelines for the new institute involving Ortiz; Robert Klein II, the measure's originator; and the 29-person oversight panel that will create guidelines and oversee research grants.

The measure was written to make it...